Clinical trialNAUnknown
Comparation Between Needles for EUS-guided Sampling of Solid Pancreatic Lesions
Prospective Randomized Study Comparing the 25-gauge Franseen Needle and the 25-gauge Standard Needle for EUS-guided Fine-needle Sampling of Solid Pancreatic Lesions Without Rapid on Site Evaluation
- Outcome
- Outcome unknown
- Phase
- NA
- Status
- Unknown
- Study type
- Interventional
- Start
- 26 November 2020
- Expected end
- April 2023
- Enrollment
- 50 participants
- Sites
- 1
- Primary outcomes
- Compare the diagnostic yield
- Sponsor
- Other
- Results posted
- No
- Last update
- 7 May 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a randomized study in order to compare the diagnostic yield (primary outcome) of EUS-guided sampling of pancreatic solid lesions obtained with the 25-gauge Franseen and the 25-gauge standard needle in patients undergoing EUS-guided sampling of pancreatic solid masses without ROSE. Secondary outcomes are the number of extra passes with each needle required to reach adequate core, possibility to perform immunohistochemistry and the adverse event rate.
Detailed description public domain (ClinicalTrials.gov)
This is a randomized trial conducted at a unique center. The aim of this study is to compare the diagnostic yield (primary outcome) of EUS-guided sampling of pancreatic solid lesions obtained with the 25-gauge Franseen and the 25-gauge standard needle in patients undergoing EUS-guided sampling of pancreatic solid masses without ROSE. Secondary outcomes are the number of extra passes with each needle required to reach adequate core, possibility to perform immunohistochemistry and the adverse event rate. Patients with a suspected solid pancreatic lesion larger than 15 mm, identified by CT or MRI and referred to EUS-guided sampling will be eligible for inclusion. Patients will be excluded in case of cystic lesion, or the lesion was not detected in EUS, or if the coagulation parameters are abnormal (INR\> 2, platelet count \< 50,000). The pancreatic mass will be puncture, for expert endoscopist, firstly with a needle according to randomization, followed by another one. Will be make a touch print with the specimen obtained with the needles and, subsequently, all the specimen will be put in formaldehyde solution for cell-block analysis. Diagnostic yield of cell block will be defined as enough histologic tissue core containing pancreatic parenchyma or tumor with dysplastic cells enough for the correct tissue diagnosis. In the presence of malignant tissue in core specimens, it will be calculated the proportion of the area positive for malignancy compared to the total area of the core and then the each needle yield will be defined.
Papers 7
- BackgroundComparison of modified wet suction technique and dry suction technique in endoscopic ultrasound-guided fine-needle aspi… DOI 10.1186/s13063-017-2380-y↗
- BackgroundEndoscopic ultrasonography-guided biopsy using a Franseen needle design: Initial assessment. DOI 10.1111/den.12769↗
- BackgroundCurrent status of diagnostic endoscopic ultrasonography in the evaluation of pancreatic mass lesions. DOI 10.1111/j.1443-1661.2011.01132.x↗
- BackgroundInfluence of on-site cytopathology evaluation on the diagnostic accuracy of endoscopic ultrasound-guided fine needle as… DOI 10.1038/ajg.2011.119↗
- BackgroundFeasibility and yield of a new EUS histology needle: results from a multicenter, pooled, cohort study. DOI 10.1016/j.gie.2011.01.053↗
- BackgroundRandomized controlled trial of endoscopic ultrasound-guided fine-needle sampling with or without suction for better cyt… DOI 10.1080/00365520802647392↗
- BackgroundEndoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. DOI 10.1016/s0016-5107(92)70385-x↗